Nektar Therapeutics (NASDAQ: NKTR) Faces Competition but Shows Promise in Drug Development

Nektar Therapeutics (NASDAQ: NKTR) is a biopharmaceutical company focusing on autoimmune diseases, oncology, and pain management.H.C. Wainwright set a price target of $135 for NKTR, indicating a potential price increase of approximately 164%.Recent Phase 2b REZOLVE-AA trial results for rezpegaldesleukin showed significant potential in treating severe-to-very-severe alopecia areata.Nektar Therapeutics (NASDAQ: NKTR) is a biopharmaceutical company focused on developing innovative medicines in areas of high un ...